AvenCell Therapeutics Inc: Valuation, Funding & Investors
AvenCell Therapeutics Inc is a clinical-stage cell therapy company specializing in the development of both autologous and allogeneic switchable CAR-T cell therapies. The company is focused on utilizing its proprietary Universal Switchable CAR-T cell therapy platform to treat a wide range of hematologic malignancies and autoimmune diseases.
Leadership & Board
- Current Number of Employees
- 59
- Current LinkedIn Followers
- 4,434
Latest Estimated Valuation
- Total Amount Raised
- $112M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $112M
- Latest Funding Round
- Series B
Employee Trend
AvenCell Therapeutics Inc had 59 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
59Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
AvenCell Therapeutics Inc had 4,434 followers as of November 2, 2026. The number of followers increased by 11 (0.25%) week-over-week.
4,434Latest Followers Count
11(0.25%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series B | $112.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Novo Holdings | Series B |
| F-Prime Capital | Series B |
| Eight Roads Ventures Japan | Series B |
| Piper Heartland Healthcare Capital | Series B |
| NYBC Ventures | Series B |
| Blackstone Life Sciences | Series B |
Similar Companies
A snapshot of private companies similar to AvenCell Therapeutics Inc, helping you discover and navigate related company profiles.
